title: Phenotypic characterization of CD8+ T cell populations in HIV disease and in anti-HIV immunity.
abstract: The CD8+ T cell population is believed to play an important role in the control of viral infection, both for suppression of viral replication and for cytotoxic activity against viral infected cells. Elevated numbers of CD8+ T cells have been demonstrated in HIV infection, and CD8+ cytotoxic T cell (CTL) activity is associated with the early, asymptomatic stage of disease. We investigated the phenotypic characteristics of the CD8 population, in whole blood, in HIV disease and determined the predominant CD8+ subpopulation involved in anti-HIV CTL activity. We found that CD8+ T cells co-expressing markers of activation (HLA-DR), memory (CD45RO, CD29), and cytotoxic activity (S6F1) were significantly elevated in the early stages of disease, while the numbers of naive (CD45RA) cells remained unchanged. Progression to AIDS resulted in an overall loss of absolute CD8+ T cells, though the percentages of CD8+ HLA-DR+ and CD8+ S6F1+ remained elevated. In contrast to patients in the late stages of disease, anti-HIVgag CTL activity, following in vitro stimulation, was present in most HIV+ asymptomatic subjects and was associated with an expansion of CD8+ HLA-DR+ and CD8+ CD45RO+ cells. The absence of CTL activity was associated with a reduced ability of these populations to expand in vitro and with a significant loss of peripheral CD4+ T cells, independent of clinical stage. We suggest that CD8+ expressing HLA-DR+ CD45RO+ and S6F1+ play an important role in anti-HIV cytotoxicity.
authors.affiliation: Edinburgh University Department of Medicine, Royal Infirmary, UK.
authors.forename: K C
authors.initials: KC
authors.lastname: Watret
authors.forename: J A
authors.initials: JA
authors.lastname: Whitelaw
authors.forename: K S
authors.initials: KS
authors.lastname: Froebel
authors.forename: A G
authors.initials: AG
authors.lastname: Bird
mesh_terms: D015703:Antigens, CD / Q000097:blood; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D016827:CD8 Antigens / Q000097:blood*; D003602:Cytotoxicity, Immunologic; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology*; D006684:HLA-DR Antigens / Q000097:blood; D006801:Humans; D016130:Immunophenotyping; D007244:Infectious Mononucleosis / Q000276:immunology; D019012:Integrin beta1; D017493:Leukocyte Common Antigens / Q000097:blood; D007958:Leukocyte Count; D016169:Lymphocyte Function-Associated Antigen-1 / Q000097:blood; D008297:Male; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D015703:Antigens, CD; D016827:CD8 Antigens; D006684:HLA-DR Antigens; D019012:Integrin beta1; D016169:Lymphocyte Function-Associated Antigen-1; D015215:Zidovudine; D017493:Leukocyte Common Antigens